Seek Labs and NAMRU EURAFCENT Enter CRADA to Evaluate Field-Deployable Diagnostics for Infectious Diseases

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Seek Labs and NAMRU EURAFCENT Enter CRADA to Evaluate Field-Deployable Diagnostics for Infectious DiseasesAuthor of the article:SALT LAKE CITY, Aug. 24, 2026 (GLOBE NEWSWIRE) — Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, today announced a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Unit (NAMRU) EURAFCENT, part of Navy Medicine Research & Development that is focused on infectious disease threats affecting military personnel, to evaluate SeekIt™, the company’s instrument-free molecular diagnostic platform. SeekIt includes a field kit and single-use device for detecting infectious diseases in forward-deployed, austere, and resource-constrained settings.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an Account“SeekIt is designed around a single principle: molecular diagnostics should go where the disease is, not the other way around,” said Kim Wirthlin, Chief Strategy Officer for Seek Labs. “SeekIt puts a full laboratory-grade molecular test—including extraction, amplification, and detection—into a handheld, instrument-free kit of discrete, individually packaged components. It is designed for forward-deployed medical teams, expeditionary operations, shipboard use, and outbreak surveillance in austere environments without the need for electricity, instruments, or cold chain.”Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againUnder the CRADA, Seek Labs and NAMRU EURAFCENT will evaluate the SeekIt™ field kit for usability and operational integration, pairing Seek Labs’ test development with NAMRU EURAFCENT’s biosurveillance, laboratory testing coordination, and definition of military use cases. The work is expected to inform future R&D pathways and additional areas of collaboration.“The SeekIt platform has the potential to revolutionize how we approach bio surveillance,” said Capt. Michael Prouty, commanding officer of NAMRU EURAFCENT, in a recent official Navy release. “In the remote and often austere settings where our forces operate, having a rapid, reliable, and field-deployable diagnostic capability is not just an advantage, it is a necessity for maintaining mission readiness and operational effectiveness.”By integrating the SeekIt™ field kit with NAMRU EURAFCENT’s biosurveillance and operational research expertise, the collaboration aims to deliver scalable, field-ready solutions that help NAMRU EURAFCENT protect warfighter health and sustain operational effectiveness in demanding environments worldwide.About Seek LabsEvery disease has a sequence. Seek Labs is a TechBio company building systems to decode, program, and resolve disease. At the core of its platform is an AI-powered intelligence layer that analyzes and translates sequences into actionable data, informing two deployment layers: Sequence Ablation Therapeutics (SAT) and molecular detection. Together, these systems form a continuous loop in which genomic data is decoded, translated into therapeutic and diagnostic outputs, and refined through real-world deployment.Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah’s collaborative life sciences ecosystem. Together with its partners, Seek Labs is building faster, smarter solutions for urgent health challenges.About NAMRU EURAFCENTNAMRU EURAFCENT, part of Navy Medicine Research & Development, conducts research, surveillance and studies of vaccines, therapeutic agents, diagnostic assays and vector control measures in the EUCOM, AFRICOM and CENTCOM Areas of Responsibility to better prevent and treat infectious diseases in support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality.Media Contact: Bridget Baldwin, Director of Communications communications@seeklabs.comThis advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.